Mid-session Paris: the CAC40 pays the luxury of staying green

(Scholarship holder.com) — LATENDANCE

The indicators remain very slightly in the green this Thursday, with a CAC40 which symbolically increased by 0.1% around 7.160 points.The CAC40 is still made up to a new record of 7.181 points in the morning.All this again thanks to luxury with Hermès at the top of the charts on a new summit.The Parisian index remains for the moment on 14 increases in the last 15 sessions!

After coming close to his records on Tuesday, Wall Street was taken up by some doubts last night, ending in slight decline.Investors have raised the back of growing fears concerning inflation, which could slow down the global recovery and bring central banks to raise their guiding rates earlier than.Inflation in the euro zone accelerated in October to reach 4.1% over a year, the Eurostat Institute confirmed on Wednesday, and in the United States, prices climbed by 6.2%.

Rising values

* A l'image du CAC40, Hermès n'en finit plus de grimper.Up 2.6% to 1.580 euros, the saddler aligns a sixth consecutive session in the green and evolves on levels never reached.Like the entire luxury sector, the title benefits full of the global recovery after the bamboo stroke of last year.In a study unveiled last week, the Bain consulting firm estimates that the luxury industry, boosted by the revival of purchases in the United States and China, could erase the effects of the Cavid-19 pandemic this year andreconnect with the levels of 2019, or even exceed them.

Bain claims that global sales of luxury products (clothing, leather goods, jewelry) could reach 283 billion euros this year, an increase of 4% at constant exchange rate compared to 2019 (some 280 billion euros),before the health crisis strikes.Sales in the sector overall fell 23% in 2020, in the heart of the pandemic, unheard of since 2009.The largest companies in the sector, such as LVMH, Hermès and Kering, have already reboundedly rebounded, releases results higher at the 2019 levels.

* LVMH gagne aussi 0,8% à 732 euros (nouveau sommet atteint ce matin) tout comme Kering à 727 euros

* Abionyx (+54% à 2,28 euros) a conclu un accord avec les actionnaires d'IRIS Pharma Holding, portant sur l'apport à la société de 100% du capital d'IRIS Pharma holding qui détient 100% d'IRIS Pharma, l'un des leaders spécialisés dans la recherche préclinique et clinique sous contrat dans le domaine de l'ophtalmologie, apport entièrement rémunéré par l'émission d'actions nouvelles Abionyx au prix fixé de 3,60 euros par action.

Decrease values

* Renault cède 0,4% à 34,5 euros.New car registrations in the European Union dropped by 30.3% in October to 665.001 units, show the data of the association of European car manufacturers.This is the worst month of October for industry since the creation of statistics.Most markets have undergone two-digit losses, including the four largest: Italy (-35.7%), Germany (-34.9%), France (-30.7%) and Spain (-20, 5%). Au niveau des constructeurs, Volkswagen (-44%) a fortement souffert le mois dernier, tout comme Daimler (-34,2%) ainsi que les Français Renault (-31,7%) et Stellantis (-33%). Seul Hyundai Group (+3,7%) s'est démarqué.

* Airbus (-0,3%) a réussi une belle moisson à Dubaï, premier grand salon aéronautique depuis le début de la pandémie il y a deux ans.The European aircraft manufacturer has garnered orders and commitments for a total of 408 aircraft (269 firm orders and 139 commitments).The agreements cover the entire range of commercial aircraft of the Toulouse group, including a first commitment for the future A350F.Airbus notably won a mega-control of more than $ 30 billion (at the catalog price) from Indigo Partners.The American businessman group specializing in low -cost air transport Bill Franke will acquire 255 A321 intended for its four airlines: Wizz Air, Frontier Airlines, Jetsmart and Voaris.

* Sanofi (-1,4%) a annoncé aujourd'hui un investissement de 180 millions de dollars dans le capital d'Owkin et la mise en place d'une nouvelle collaboration stratégique autour de programmes de recherche et développement sur quatre formes de cancer, prévoyant un paiement initial de 90 millions de dollars échelonné sur trois ans, assorti de paiements d'étape supplémentaires.Owkin is a company specializing in artificial intelligence (AI) and precision medicine that develops predictive artificial intelligence models applied to biomedicine among the best in their category, as well as solid sets of data data.This collaboration, which aims to optimize the design of clinical trials and detect predictive biomarkers of diseases and therapeutic results, will accompany the growth of the Sanofi oncology development portfolio in three major areas: lung cancer, thebreast cancer and multiple myeloma.

* Vallourec décroche de 16% sur les 6 euros, sanctionné après son léger avertissement.The specialist in welding -free metal tubes now anticipates a gross operating result for the whole year close to the bottom of the objective of 475 to 525 communicated to me previously due to the recent drop in iron ore prices.In addition, a dynamic of controls stronger than expected for deliveries in 2022, combined with the evolution of prices of raw materials and energy, will lead to a greater increase in stocks at the end of the year.Consequently, Vallourec now tables a cash flow consumption between -380 and -300 ME for 2021 (against 160 to 240 me previously), mainly due to the increase in working capital requirement in connection with the resumption ofactivity, and including occasional costs associated with financial restructuring.In the third quarter, the group released a RB of 128 ME, up 80% over a year (129.8 M of consensus), for a turnover of 834 ME (885 I expected), up 16, 4%.The available cash flow emerged at -103 Me, against 35 Me in the third quarter 2020.